<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK538658" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK538658/" /><meta name="ncbi_pagename" content="FARS2 Deficiency - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>FARS2 Deficiency - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="FARS2 Deficiency" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/03/14" /><meta name="citation_author" content="Mohammed Almannai" /><meta name="citation_author" content="Eissa Faqeih" /><meta name="citation_author" content="Ayman W El-Hattab" /><meta name="citation_author" content="Lee-Jun C Wong" /><meta name="citation_pmid" content="30869852" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK538658/" /><meta name="citation_keywords" content="FARS2-Related Infantile-Onset Epileptic Mitochondrial Encephalopathy" /><meta name="citation_keywords" content="FARS2-Related Later-Onset Spastic Paraplegia" /><meta name="citation_keywords" content="Phenylalanine--tRNA ligase, mitochondrial" /><meta name="citation_keywords" content="FARS2" /><meta name="citation_keywords" content="FARS2 Deficiency" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="FARS2 Deficiency" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Mohammed Almannai" /><meta name="DC.Contributor" content="Eissa Faqeih" /><meta name="DC.Contributor" content="Ayman W El-Hattab" /><meta name="DC.Contributor" content="Lee-Jun C Wong" /><meta name="DC.Date" content="2019/03/14" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK538658/" /><meta name="description" content="The spectrum of FARS2 deficiency ranges from the infantile-onset phenotype, characterized by epileptic encephalopathy with lactic acidosis and poor prognosis (70% of affected individuals), to the later-onset phenotype, characterized by spastic paraplegia, less severe neurologic manifestations, and longer survival (30% of affected individuals). To date FARS2 deficiency has been reported in 37 individuals from 25 families." /><meta name="og:title" content="FARS2 Deficiency" /><meta name="og:type" content="book" /><meta name="og:description" content="The spectrum of FARS2 deficiency ranges from the infantile-onset phenotype, characterized by epileptic encephalopathy with lactic acidosis and poor prognosis (70% of affected individuals), to the later-onset phenotype, characterized by spastic paraplegia, less severe neurologic manifestations, and longer survival (30% of affected individuals). To date FARS2 deficiency has been reported in 37 individuals from 25 families." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK538658/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/fars2-def/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK538658/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE888116DFC890010000000004A3023E.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK538658_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK538658_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ee/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/fbln5-cutis-laxa/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK538658_"><span class="title" itemprop="name">FARS2 Deficiency</span></h1><p class="contrib-group"><span itemprop="author">Mohammed Almannai</span>, MD, FAAP, FACMG, <span itemprop="author">Eissa Faqeih</span>, MD, <span itemprop="author">Ayman W El-Hattab</span>, MD, FAAP, FACMG, and <span itemprop="author">Lee-Jun C Wong</span>, PhD, FACMG.</p><a data-jig="ncbitoggler" href="#__NBK538658_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK538658_ai__"><div class="contrib half_rhythm"><span itemprop="author">Mohammed Almannai</span>, MD, FAAP, FACMG<div class="affiliation small">Medical Genetics and Metabolic Consultant, Section of Medical Genetics<br />King Fahad Medical City<br />Riyadh, Saudi Arabia<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="as.dem.cmfk@iannamlam" class="oemail">as.dem.cmfk@iannamlam</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Eissa Faqeih</span>, MD<div class="affiliation small">Medical Genetics and Metabolic Consultant, Section of Medical Genetics<br />King Fahad Medical City<br />Riyadh, Saudi Arabia<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="as.dem.cmfk@hieqafe" class="oemail">as.dem.cmfk@hieqafe</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Ayman W El-Hattab</span>, MD, FAAP, FACMG<div class="affiliation small">Associate Professor, Department of Clinical Sciences<br />College of Medicine<br />University of Sharjah<br />Sharjah, United Arab Emirates<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.oohay@wabattahle" class="oemail">moc.oohay@wabattahle</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Lee-Jun C Wong</span>, PhD, FACMG<div class="affiliation small">Professor, Department of Molecular and Human Genetics<br />Baylor College of Medicine<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mcb@gnowjl" class="oemail">ude.mcb@gnowjl</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">March 14, 2019</span>.</p><p><em>Estimated reading time: 20 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="fars2-def.Summary" itemprop="description"><h2 id="_fars2-def_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>The spectrum of FARS2 deficiency ranges from the infantile-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, characterized by epileptic encephalopathy with lactic acidosis and poor prognosis (70% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals), to the later-onset phenotype, characterized by spastic paraplegia, less severe neurologic manifestations, and longer survival (30% of affected individuals). To date FARS2 deficiency has been reported in 37 individuals from 25 families.</p><ul><li class="half_rhythm"><div><i>Infantile-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</i> Seizures are difficult to control and may progress quickly at an early age to intractable seizures with frequent status epilepticus; some children have hypsarrhythmia on EEG. All have developmental delay; most are nonverbal and unable to walk. Feeding difficulties are common. More than half of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children die in early childhood.</div></li><li class="half_rhythm"><div><i>Later-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</i> All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have spastic paraplegia manifested by weakness, spasticity, and exaggerated reflexes of the lower extremities associated with walking difficulties; some have developmental delay/intellectual disability; some have brief seizures that resolve over time.</div></li></ul></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of FARS2 deficiency is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with suggestive findings and <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>FARS2</i> identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment is symptomatic and best provided by a multidisciplinary team comprising neurodevelopmental pediatricians, neurologists, physiatrists, occupational and physical therapists, feeding specialists, speech and language therapists, and social workers to assure adequate family support.</p><p><i>Surveillance:</i> For those with infantile onset: routine monitoring of feeding and nutrition, seizure control, developmental progress, OT/PT needs, and family social support.</p><p>For those with later onset: routine monitoring of OT/PT needs (e.g., mobility and activities of daily living), orthopedic complications (contractures, scoliosis, foot deformities), seizure control, speech and language development, and educational and social needs.</p><p><i>Agents/circumstances to avoid:</i> While valproic acid can induce liver failure in persons with mitochondrial diseases, some individuals with FARS2 deficiency received valproic acid with no evidence of liver dysfunction or worsening of existing liver disease. Given the limited number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals reported to date, no general recommendation can be made.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>FARS2 deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Once the <i>FARS2</i> pathogenic variants have been identified in an affected family member, <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> of at-risk relatives, prenatal testing for a pregnancy at increased risk, and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="fars2-def.GeneReview_Scope"><h2 id="_fars2-def_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="fars2-def.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK538658/table/fars2-def.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fars2-def.Td_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fars2-def.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FARS2 Deficiency: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_fars2-def.Td_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div><i>FARS2</i>-related infantile-onset epileptic mitochondrial encephalopathy</div></li><li class="half_rhythm"><div><i>FARS2</i>-related later-onset spastic paraplegia</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#fars2-def.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="fars2-def.TF.d.1"><p class="no_margin">For other genetic causes of these phenotypes, see <a href="#fars2-def.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div></div><div id="fars2-def.Diagnosis"><h2 id="_fars2-def_Diagnosis_">Diagnosis</h2><p>FARS2 deficiency comprises a spectrum of disease severity that ranges between two phenotypes: infantile-onset epileptic mitochondrial encephalopathy and less severe, later-onset spastic paraplegia.</p><p>Formal diagnostic criteria for FARS2 deficiency have not been established.</p><div id="fars2-def.Suggestive_Findings"><h3>Suggestive Findings</h3><p>The two phenotypes known to date to be associated with FARS2 deficiency are infantile-onset epileptic mitochondrial encephalopathy and later-onset spastic paraplegia.</p><p><b><i>FARS2-</i>related infantile-onset epileptic mitochondrial encephalopathy should be considered</b> in children from birth to age six months with the following clinical, laboratory, and imaging findings.</p><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>Developmental delay</div></li><li class="half_rhythm"><div>Truncal hypotonia</div></li></ul><p><b>Laboratory findings</b></p><ul><li class="half_rhythm"><div>Elevated plasma lactate levels; seen in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#fars2-def.REF.almannai.2018.281">Almannai et al 2018</a>]</div></li><li class="half_rhythm"><div>Elevated cerebrospinal fluid lactate</div></li><li class="half_rhythm"><div>Electron transport chain enzyme activity; ranges from normal to low complex I activity, low complex IV activity, or combined deficiency of both</div></li><li class="half_rhythm"><div>Elevated liver enzymes (ALT, AST) and gamma-glutamyl transferase in some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</div></li></ul><p><b>Neuroimaging findings</b></p><ul><li class="half_rhythm"><div><b>MRI.</b> Nonspecific diffuse cortical and subcortical cerebral atrophy particularly later in the disease course; thinning of the corpus callosum (reflecting reduced cerebral white matter volume)</div><div>Occasional findings:</div><ul><li class="half_rhythm"><div>Evidence of deep cerebellar white matter involvement and hyperintensity of the hila of the dentate nuclei [<a class="bk_pop" href="#fars2-def.REF.raviglione.2016.3004">Raviglione et al 2016</a>, <a class="bk_pop" href="#fars2-def.REF.almannai.2018.281">Almannai et al 2018</a>]</div></li><li class="half_rhythm"><div>Abnormalities in basal ganglia signal intensity [<a class="bk_pop" href="#fars2-def.REF.elo.2012.4521">Elo et al 2012</a>, <a class="bk_pop" href="#fars2-def.REF.shamseldin.2012.234">Shamseldin et al 2012</a>, <a class="bk_pop" href="#fars2-def.REF.walker.2016.1127">Walker et al 2016</a>]</div></li><li class="half_rhythm"><div>Cystic degeneration with diffuse and symmetric swelling and abnormal signal intensity of the cerebral subcortical white matter, which was completely suppressed on fluid-attenuated inversion recovery (FLAIR) sequence</div></li></ul></li><li class="half_rhythm"><div><b>MR spectroscopy (MRS).</b> High lactate peak</div></li></ul><p><b><i>FARS2-</i>related later-onset spastic paraplegia should be considered</b> in individuals age six months and older with the following clinical and laboratory findings.</p><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div>Spastic paraplegia, seen in all individuals with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, characterized by lower-extremity weakness, spasticity, and exaggerated reflexes associated with walking difficulties</div></li><li class="half_rhythm"><div>Spastic paraplegia can be pure or can be complicated by other less common neurologic findings including the following:</div><ul><li class="half_rhythm"><div>Developmental delay / intellectual disability</div></li><li class="half_rhythm"><div>Brief seizures that resolve over time</div></li></ul></li></ul><p><b>Laboratory findings.</b> Elevated plasma lactate</p></div><div id="fars2-def.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of FARS2 deficiency <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with <a href="#fars2-def.Suggestive_Findings">suggestive findings</a> and <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>FARS2</i> identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK538658/table/fars2-def.T.molecular_genetic_testing_us/?report=objectonly" target="object" rid-figpopup="figfars2defTmoleculargenetictestingus" rid-ob="figobfars2defTmoleculargenetictestingus">Table 1</a>).</p><p>Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of FARS2 deficiency is indistinguishable from many other inherited disorders presenting with infantile epileptic encephalopathy or spastic paraplegia, recommended <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches include use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> or <b>comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><p>Note: Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (<a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>FARS2</i>, followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>) is rarely useful and typically NOT recommended.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>FARS2</i> and other genes of interest (see <a href="#fars2-def.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. Of note, given the rarity of FARS2 deficiency, some panels for infantile epileptic encephalopathy and/or spastic paraplegia may not include <i>FARS2</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For FARS2 deficiency a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK538658/table/fars2-def.T.molecular_genetic_testing_us/?report=objectonly" target="object" rid-figpopup="figfars2defTmoleculargenetictestingus" rid-ob="figobfars2defTmoleculargenetictestingus">Table 1</a>).</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is another good option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</div><div class="half_rhythm">If <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> is not diagnostic, <b><a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a></b> (when clinically available) may be considered to detect (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="fars2-def.T.molecular_genetic_testing_us" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in FARS2 Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK538658/table/fars2-def.T.molecular_genetic_testing_us/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fars2-def.T.molecular_genetic_testing_us_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fars2-def.T.molecular_genetic_testing_us_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_fars2-def.T.molecular_genetic_testing_us_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_fars2-def.T.molecular_genetic_testing_us_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method&#x000a0;<sup>3</sup></th></tr></thead><tbody><tr><td headers="hd_h_fars2-def.T.molecular_genetic_testing_us_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>FARS2</i></td><td headers="hd_h_fars2-def.T.molecular_genetic_testing_us_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_fars2-def.T.molecular_genetic_testing_us_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~95%-98%</td></tr><tr><td headers="hd_h_fars2-def.T.molecular_genetic_testing_us_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_fars2-def.T.molecular_genetic_testing_us_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3 reported</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="fars2-def.TF.1.1"><p class="no_margin">See <a href="/books/NBK538658/#fars2-def.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="fars2-def.TF.1.2"><p class="no_margin">See <a href="#fars2-def.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="fars2-def.TF.1.3"><p class="no_margin"><a class="bk_pop" href="#fars2-def.REF.elo.2012.4521">Elo et al [2012]</a>, <a class="bk_pop" href="#fars2-def.REF.shamseldin.2012.234">Shamseldin et al [2012]</a>, <a class="bk_pop" href="#fars2-def.REF.almalki.2014.56">Almalki et al [2014]</a>, <a class="bk_pop" href="#fars2-def.REF.vernon.2015.1147">Vernon et al [2015]</a>, <a class="bk_pop" href="#fars2-def.REF.de_kovel.2016.568">de Kovel et al [2016]</a>, <a class="bk_pop" href="#fars2-def.REF.raviglione.2016.3004">Raviglione et al [2016]</a>, <a class="bk_pop" href="#fars2-def.REF.walker.2016.1127">Walker et al [2016]</a>, <a class="bk_pop" href="#fars2-def.REF.yang.2016.165">Yang et al [2016]</a>, <a class="bk_pop" href="#fars2-def.REF.cho.2017.118">Cho et al [2017]</a>, <a class="bk_pop" href="#fars2-def.REF.vantroys.2017.172">Vantroys et al [2017]</a>, <a class="bk_pop" href="#fars2-def.REF.almannai.2018.281">Almannai et al [2018]</a>, <a class="bk_pop" href="#fars2-def.REF.sahai.2018.1128">Sahai et al [2018]</a></p></div></dd><dt>4. </dt><dd><div id="fars2-def.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="fars2-def.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications. Gene-targeted deletion/duplication testing will detect deletions ranging from a single exon to the whole gene; however, breakpoints of large deletions and/or deletion of adjacent genes (e.g., those described by <a class="bk_pop" href="#fars2-def.REF.almalki.2014.56">Almalki et al [2014]</a>) may not be detected by these methods.</p></div></dd></dl></div></div></div></div></div><div id="fars2-def.Clinical_Characteristics"><h2 id="_fars2-def_Clinical_Characteristics_">Clinical Characteristics</h2><div id="fars2-def.Clinical_Description"><h3>Clinical Description</h3><p>The spectrum of FARS2 deficiency ranges between two phenotypes: infantile-onset disease characterized by epileptic encephalopathy with lactic acidosis and poor prognosis (70% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals) and later-onset spastic paraplegia (30% of affected individuals) associated with less severe neurologic manifestations and longer survival.</p><p>The findings in the 37 individuals with FARS2 deficiency reported to date are summarized in <a class="figpopup" href="/books/NBK538658/table/fars2-def.T.clinical_neuroimaging_and_me/?report=objectonly" target="object" rid-figpopup="figfars2defTclinicalneuroimagingandme" rid-ob="figobfars2defTclinicalneuroimagingandme">Table 2</a> [<a class="bk_pop" href="#fars2-def.REF.elo.2012.4521">Elo et al 2012</a>, <a class="bk_pop" href="#fars2-def.REF.shamseldin.2012.234">Shamseldin et al 2012</a>, <a class="bk_pop" href="#fars2-def.REF.almalki.2014.56">Almalki et al 2014</a>, <a class="bk_pop" href="#fars2-def.REF.vernon.2015.1147">Vernon et al 2015</a>, <a class="bk_pop" href="#fars2-def.REF.de_kovel.2016.568">de Kovel et al 2016</a>, <a class="bk_pop" href="#fars2-def.REF.raviglione.2016.3004">Raviglione et al 2016</a>, <a class="bk_pop" href="#fars2-def.REF.walker.2016.1127">Walker et al 2016</a>, <a class="bk_pop" href="#fars2-def.REF.yang.2016.165">Yang et al 2016</a>, <a class="bk_pop" href="#fars2-def.REF.cho.2017.118">Cho et al 2017</a>, <a class="bk_pop" href="#fars2-def.REF.vantroys.2017.172">Vantroys et al 2017</a>, <a class="bk_pop" href="#fars2-def.REF.almannai.2018.281">Almannai et al 2018</a>, <a class="bk_pop" href="#fars2-def.REF.sahai.2018.1128">Sahai et al 2018</a>].</p><div id="fars2-def.T.clinical_neuroimaging_and_me" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Clinical, Neuroimaging, and Metabolic Findings in FARS2 Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK538658/table/fars2-def.T.clinical_neuroimaging_and_me/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fars2-def.T.clinical_neuroimaging_and_me_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Infantile Onset</th><th id="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Later Onset</th></tr></thead><tbody><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Number of families</b></td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">19</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Number of individuals</b></td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">26</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Age at presentation</b></td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Birth-6 mos (median 35 days; mean 62 days)</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6 mos-5 yrs (median 2 yrs; mean 2.1 yrs)</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Outcome</b></td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Alive</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8/23 (age range: 4 mos-3.5 yrs; median 1.6 yrs; mean 1.8 yrs)</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11/11 (age range: 5.5-41 yrs; median 17 yrs; mean 20 yrs)&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deceased</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15/23 (age range 2 days-15 yrs; median 4 mos; mean 20 mos)</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0/11</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic manifestations</b></td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DD/ID</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">24/24</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6/11</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Truncal hypotonia</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16/19</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2/9</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Spasticity</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11/19</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10/10 (spastic paraplegia)</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Seizures</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">24/25</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3/11</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neuroimaging</b></td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MRI: brain atrophy</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15/19</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2/11</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">MRI: thin corpus callosum</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12/19</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0/11</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">MRI: hyperintensity of dentate nuclei</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4/19</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/11</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">MRS: increased lactate peak</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8/11</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Liver</b></td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Enlarged</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5/19</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0/11</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Increased transaminases</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14/19</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0/11</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Increased GGT&#x000a0;<sup>2</sup></td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8/8</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Growth</b></td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Failure to thrive</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9/17</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0/8</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Microcephaly</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14/18</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0/7</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Metabolic</b></td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lactic acidosis</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">21/22</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3/10</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Increased CSF lactate</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7/7</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2/3</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Increased plasma alanine</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13/17</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4/6</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>ETC enzyme activity</b></td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low complex I activity</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3/7</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/2</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Low complex IV activity</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4/7</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/2</td></tr><tr><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Normal activity</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2/7</td><td headers="hd_h_fars2-def.T.clinical_neuroimaging_and_me_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0/2</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">CSF = cerebrospinal fluid; DD = developmental delay; ETC = electron transport chain; GGT = gamma-glutamyl transferase; ID = intellectual disability; MRI = magnetic resonance imaging; MRS = magnetic resonance spectroscopy</p></div></dd><dt>1. </dt><dd><div id="fars2-def.TF.2.1"><p class="no_margin">One individual who had hypoxic-ischemic encephalopathy was not included in age-of-onset calculations. For another individual (who had seizures with a normal EEG following vaccination at age 2 months), age of onset was considered to be 3 years (the age at which he was evaluated for developmental delay [<a class="bk_pop" href="#fars2-def.REF.vernon.2015.1147">Vernon et al 2015</a>].</p></div></dd><dt>2. </dt><dd><div id="fars2-def.TF.2.2"><p class="no_margin">Elevations up to 1,700 U/L were observed.</p></div></dd></dl></div></div></div><div id="fars2-def.InfantileOnset_Epileptic_Mitoc"><h4>Infantile-Onset Epileptic Mitochondrial Encephalopathy</h4><p><b>Seizures.</b> Seizures were the most common presenting manifestation. Of note, the only infant who did not have seizures was a premature infant who died at age two days.</p><p>Seizures tend to be focal with associated facial or eye twitching and myoclonic jerks of the extremities. Other types of seizures include generalized tonic-clonic, infantile spasms, and epilepsia partialis continua. Seizures are difficult to control and may progress quickly at an early age to intractable seizures with frequent status epilepticus. EEG usually shows multifocal epileptic discharges. A few children had hypsarrhythmia.</p><p><b>Developmental delay.</b> All children had developmental delays affecting all domains. Most did not develop expressive language and were not able to walk. Regression was noted in a few individuals after the onset of seizures.</p><p><b>Variable degree of truncal hypotonia, observed early in the course of the disease,</b> is usually associated with appendicular hypertonia and long tract signs.</p><p>Several children with the infantile-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> developed central visual impairment, usually with normal fundoscopic examination (i.e., without optic atrophy or retinal changes). One child was reported to have coarse retinal pigmentation [<a class="bk_pop" href="#fars2-def.REF.elo.2012.4521">Elo et al 2012</a>].</p><p><b>Growth.</b> Failure to thrive reflects the often observed feeding and swallowing difficulties. Microcephaly, which is of postnatal onset, results from diffuse cerebral atrophy that develops later in the disease course.</p><p><b>Liver disease.</b> There was no significant elevation in total and direct bilirubin to suggest cholestasis. Liver involvement of unknown cause manifested as enlarged liver in some individuals. In one child, liver biopsy showed enlarged hepatocytes and increased amounts of glycogen and lysosomal iron and copper. The neuropathologic brain findings of this child met diagnostic criteria for Alpers-Huttenlocher disease [<a class="bk_pop" href="#fars2-def.REF.elo.2012.4521">Elo et al 2012</a>] (see also <a href="/books/n/gene/alpers/"><i>POLG</i>-Related Disorders</a>).</p><p>Of note: Although some children were treated with valproic acid (which can induce liver failure in persons with mitochondrial disorders) [<a class="bk_pop" href="#fars2-def.REF.kr_henb_hl.2000.346">Kr&#x000e4;henb&#x000fc;hl et al 2000</a>], none had evidence of liver dysfunction or worsening of existing liver disease [<a class="bk_pop" href="#fars2-def.REF.elo.2012.4521">Elo et al 2012</a>, <a class="bk_pop" href="#fars2-def.REF.walker.2016.1127">Walker et al 2016</a>, <a class="bk_pop" href="#fars2-def.REF.cho.2017.118">Cho et al 2017</a>].</p><p><b>Less frequently reported manifestations</b> include the following:</p><ul><li class="half_rhythm"><div>Strabismus [<a class="bk_pop" href="#fars2-def.REF.raviglione.2016.3004">Raviglione et al 2016</a>]</div></li><li class="half_rhythm"><div>Nystagmus [<a class="bk_pop" href="#fars2-def.REF.raviglione.2016.3004">Raviglione et al 2016</a>]</div></li><li class="half_rhythm"><div>Non-epileptic myoclonus [<a class="bk_pop" href="#fars2-def.REF.almalki.2014.56">Almalki et al 2014</a>, <a class="bk_pop" href="#fars2-def.REF.walker.2016.1127">Walker et al 2016</a>]</div></li></ul><p><b>Prognosis.</b> More than half of the reported children with the infantile-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> died early. Causes of death included uncontrolled seizures and secondary infections. Several children with profound developmental delay and uncontrolled seizures died shortly after the decision was made to provide palliative care only.</p></div><div id="fars2-def.FARS2Related_LaterOnset_Spasti"><h4><i>FARS2</i>-Related Later-Onset Spastic Paraplegia</h4><p>All individuals with the later-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> had spastic paraplegia, manifest as weakness, spasticity, and exaggerated reflexes of the lower extremities associated with walking difficulties. Spastic paraplegia could be pure or complicated by other less common neurologic findings including the following:</p><ul><li class="half_rhythm"><div>Developmental delay / intellectual disability that is less severe than the DD/ID seen in the infantile-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (e.g., 5/6 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals developed expressive language)</div></li><li class="half_rhythm"><div>Brief seizures that resolved over time [<a class="bk_pop" href="#fars2-def.REF.vernon.2015.1147">Vernon et al 2015</a>, <a class="bk_pop" href="#fars2-def.REF.vantroys.2017.172">Vantroys et al 2017</a>]</div></li></ul><p>Less frequently reported neurologic findings:</p><ul><li class="half_rhythm"><div>Startle myoclonus [<a class="bk_pop" href="#fars2-def.REF.vantroys.2017.172">Vantroys et al 2017</a>]</div></li><li class="half_rhythm"><div>Inattention tremor [<a class="bk_pop" href="#fars2-def.REF.vernon.2015.1147">Vernon et al 2015</a>, <a class="bk_pop" href="#fars2-def.REF.vantroys.2017.172">Vantroys et al 2017</a>]</div></li><li class="half_rhythm"><div>Bradykinesia [<a class="bk_pop" href="#fars2-def.REF.vantroys.2017.172">Vantroys et al 2017</a>]</div></li><li class="half_rhythm"><div>Dystonia [<a class="bk_pop" href="#fars2-def.REF.vantroys.2017.172">Vantroys et al 2017</a>]</div></li><li class="half_rhythm"><div>Dysarthria [<a class="bk_pop" href="#fars2-def.REF.vernon.2015.1147">Vernon et al 2015</a>, <a class="bk_pop" href="#fars2-def.REF.vantroys.2017.172">Vantroys et al 2017</a>]</div></li></ul><p>Less frequently reported manifestations:</p><ul><li class="half_rhythm"><div>Strabismus [<a class="bk_pop" href="#fars2-def.REF.vernon.2015.1147">Vernon et al 2015</a>]</div></li><li class="half_rhythm"><div>Scoliosis [<a class="bk_pop" href="#fars2-def.REF.vernon.2015.1147">Vernon et al 2015</a>, <a class="bk_pop" href="#fars2-def.REF.vantroys.2017.172">Vantroys et al 2017</a>]</div></li></ul><p><b>Prognosis.</b> All 11 individuals with the later-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> were alive at the time of reporting. Three were able to walk independently; the remainder depended on a walker or wheelchair for mobility. Five of the 11 individuals had normal speech, five had dysarthric speech, and one was nonverbal. Five of the 11 had normal cognition; the remainder had variable, mostly mild intellectual disability.</p></div></div><div id="fars2-def.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>It is difficult to establish a <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation in FARS2 deficiency given the limited number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and the complication of compound heterozygosity in such studies.</p><p>All 14 individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the most commonly reported variant, <a class="figpopup" href="/books/NBK538658/table/fars2-def.T.notable_fars2_pathogenic_var/?report=objectonly" target="object" rid-figpopup="figfars2defTnotablefars2pathogenicvar" rid-ob="figobfars2defTnotablefars2pathogenicvar">p.Tyr144Cys</a>, had the infantile-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (see Table 9).</p><p>Although the number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals reported to date is small, the infantile-onset and later-onset phenotypes have not shared the same genotypes.</p></div><div id="fars2-def.Nomenclature"><h3>Nomenclature</h3><p><i>FARS2</i>-related infantile-onset epileptic mitochondrial encephalopathy may also be referred to as combined oxidative phosphorylation deficiency 14 or phenylalanyl aminoacyl tRNA synthetase deficiency.</p><p><i>FARS2</i>-related later-onset spastic paraplegia may also be referred to as <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> spastic paraplegia 77 (SPG77).</p></div><div id="fars2-def.Prevalence"><h3>Prevalence</h3><p>FARS2 deficiency is rare; the exact prevalence is unknown. To date, 37 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals from 25 families have been reported.</p><p>The 25 families belong to different ethnic groups.</p><ul><li class="half_rhythm"><div>Eleven families (all with children with the infantile-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>) were Arabs, ten from Saudi Arabia and one from Iraq. In all but two families, the parents were <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a>.</div></li><li class="half_rhythm"><div>Other <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> populations include Asian, European, North American, <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a>, and Hispanic.</div></li></ul></div></div><div id="fars2-def.Genetically_Related_Allelic_Di"><h2 id="_fars2-def_Genetically_Related_Allelic_Di_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>FARS2</i>.</p></div><div id="fars2-def.Differential_Diagnosis"><h2 id="_fars2-def_Differential_Diagnosis_">Differential Diagnosis</h2><p>Phenotypic features associated with <i>FARS2</i> pathogenic variants are not sufficient to diagnose FARS2 deficiency.</p><p>For children with a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> consistent with <b>infantile-onset epileptic mitochondrial encephalopathy</b>, all genes known to be associated with early-infantile epileptic encephalopathy (&#x0003e;65 have been identified; see <a href="http://omim.org/phenotypicSeries/PS308350" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM Phenotypic Series</a>) should be included in the differential diagnosis.</p><p>For individuals with <b>later-onset spastic paraplegia</b>, all genes known to be associated with complicated spastic paraplegia (see <a href="/books/n/gene/hsp/">Hereditary Spastic Paraplegia Overview</a>) should be included in the differential diagnosis. Because some of the individuals with the later-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> were diagnosed initially to have cerebral palsy (CP), this diagnosis should be considered in individuals with a diagnosis of CP, especially when it progresses over time or the family history is positive.</p></div><div id="fars2-def.Management"><h2 id="_fars2-def_Management_">Management</h2><div id="fars2-def.Evaluations_Following_Initial"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with FARS2 deficiency, the evaluations summarized in <a class="figpopup" href="/books/NBK538658/table/fars2-def.T.recommended_evaluations_foll/?report=objectonly" target="object" rid-figpopup="figfars2defTrecommendedevaluationsfoll" rid-ob="figobfars2defTrecommendedevaluationsfoll">Table 3</a> and <a class="figpopup" href="/books/NBK538658/table/fars2-def.T.recommended_evaluations_foll_1/?report=objectonly" target="object" rid-figpopup="figfars2defTrecommendedevaluationsfoll1" rid-ob="figobfars2defTrecommendedevaluationsfoll1">Table 4</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended.</p><div id="fars2-def.T.recommended_evaluations_foll" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with FARS2 Deficiency: Infantile-Onset Epileptic Encephalopathy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK538658/table/fars2-def.T.recommended_evaluations_foll/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fars2-def.T.recommended_evaluations_foll_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Constitutional</b></td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess height, weight, head circumference.</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FTT is a significant issue for all patients.</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess for seizures.</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Seizures are usually focal but other forms are possible. EEG usually shows multifocal epileptic discharges.</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Assess for myoclonus.</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Eye &#x00026; facial twitching; myoclonic jerks of extremities</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Assess for hypotonia.</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Axial hypotonia could be associated w/appendicular hypertonia.</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Development</b></td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Developmental assessment</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incl assessment of age-appropriate motor, speech/language, cognitive skills</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Ophthalmologic</b></td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess visual acuity.</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Central visual impairment (i.e., w/o retinal or optic nerve changes) is common.</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Physical medicine &#x00026; rehabilitation/PT/OT evaluation</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess tone &#x00026; spasticity.</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Gastrointestinal/</b><br /><b>Feeding</b></td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gastroenterology / nutrition / feeding team evaluation</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess swallowing, feeding, &#x00026; nutritional status to determine safety of oral vs gastrostomy feeding.</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Assess for evidence of hepatic involvement.</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Liver enzymes &#x00026; hepatic ultrasound examination</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Respiratory</b></td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Assess airway, pulmonary function, &#x00026; secretion management.</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sleep study to assess for apnea</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Miscellaneous/</b><br /><b>Other</b></td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">FTT = failure to thrive; OT = occupational therapy; PT = physical therapy</p></div></dd></dl></div></div></div><div id="fars2-def.T.recommended_evaluations_foll_1" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with FARS2 Deficiency: Later-Onset Spastic Paraplegia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK538658/table/fars2-def.T.recommended_evaluations_foll_1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fars2-def.T.recommended_evaluations_foll_1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess for seizures.</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Seizures are uncommon &#x00026; usually brief and self limited.</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Assess for truncal hypotonia &#x00026;/or spastic paraplegia</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lower-limb spasticity w/weakness, hyperreflexia, &#x00026; abnormal gait</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Assess for myoclonus, tremor, bradykinesia, dystonia, dysarthria.</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Findings that can be seen on occasion</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Orthopedic, physical medicine &#x00026; rehabilitation, PT, &#x00026; OT evaluation</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess tone, spasticity, range of motion, gait, &#x00026; need for assistive devices.</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Development</b></td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Developmental assessment</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incl assessment of age-appropriate motor, speech/language, cognitive, vocational skills</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Speech</b></td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assessment by a speech pathologist</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For those w/dysarthria</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Miscellaneous/</b><br /><b>Other</b></td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_fars2-def.T.recommended_evaluations_foll_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">OT = occupational therapy; PT = physical therapy</p></div></dd></dl></div></div></div></div><div id="fars2-def.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Treatment is symptomatic and best provided by a multidisciplinary team comprising neurodevelopmental pediatricians, neurologists, physiatrists, occupational and physical therapists, feeding specialists, speech and language therapists, and social workers to assure adequate family support.</p><div id="fars2-def.T.treatment_of_manifestations" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with FARS2 Deficiency: Infantile-Onset Epileptic Encephalopathy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK538658/table/fars2-def.T.treatment_of_manifestations/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fars2-def.T.treatment_of_manifestations_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/<br />Concern</th><th id="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Central visual impairment</b></td><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No specific treatment; early intervention to help stimulate visual development</td><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Poor weight gain/</b><br /><b>Failure to thrive</b></td><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Feeding therapy; gastrostomy tube placement may be required for persistent feeding issues</td><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low threshold for clinical feeding evaluation &#x00026;/or radiographic swallowing study when showing clinical signs or symptoms of dysphagia</td></tr><tr><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Respiratory insufficiency</b></td><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard treatment per respiratory review</td><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Seizures</b></td><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment by an experienced neurologist</td><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Most common AEDs (e.g., levetriacetam, phenobarbital, clobazam, lacosamide) are not successful in controlling seizures.&#x000a0;<sup>1,&#x000a0;2</sup></td></tr><tr><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Family/</b><br /><b>Community</b></td><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Ensure appropriate social work involvement to connect families w/local resources, respite, &#x00026; support.</div></li><li class="half_rhythm"><div>Coordinate care to manage multiple subspecialty appointments, equipment, medications, &#x00026; supplies.</div></li></ul>
</td><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ongoing assessment of need for palliative care involvement &#x00026;/or home nursing</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AEDs = antiepileptic drugs</p></div></dd><dt>1. </dt><dd><div id="fars2-def.TF.5.1"><p class="no_margin">Education of parents regarding common seizure presentations is appropriate. For information on non-medical interventions and coping strategies for parents or caregivers of children diagnosed with epilepsy, see <a href="http://www.epilepsy.com/sites/core/files/atoms/files/English_Toolkit_updated%202014.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Epilepsy &#x00026; My Child Toolkit</a>.</p></div></dd><dt>2. </dt><dd><div id="fars2-def.TF.5.2"><p class="no_margin">One child remained seizure-free for 23 months on vigabatrin 50 mg/kg/day. He had also received adrenocorticotropic hormone (ACTH), which was tapered off over 8 weeks [<a class="bk_pop" href="#fars2-def.REF.raviglione.2016.3004">Raviglione et al 2016</a>]. Another child developed infantile spasms at age 6 months that resolved with prednisolone; however, refractory seizures occurred 6 months later [<a class="bk_pop" href="#fars2-def.REF.almalki.2014.56">Almalki et al 2014</a>].</p></div></dd></dl></div></div></div><div id="fars2-def.T.treatment_of_manifestations_1" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with FARS2 Deficiency: Later-Onset Spastic Paraplegia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK538658/table/fars2-def.T.treatment_of_manifestations_1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fars2-def.T.treatment_of_manifestations_1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/<br />Concern</th><th id="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Spasticity</b></td><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Orthopedics / physical medicine &#x00026; rehabilitation / PT / OT incl stretching to avoid contractures &#x00026; falls</td><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider need for positioning &#x00026; mobility devices, disability parking placard</td></tr><tr><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Antispasticity medications (e.g., oral or intrathecal baclofen)</div></li><li class="half_rhythm"><div>Botulinum toxin injections</div></li><li class="half_rhythm"><div>Surgical interventions to reduce spasticity</div></li></ul>
</td><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Seizures</b></td><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment by experienced neurologist</td><td headers="hd_h_fars2-def.T.treatment_of_manifestations_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Standard treatment w/AEDs by experienced neurologist</div></li><li class="half_rhythm"><div>See footnote 1</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AEDs = antiepileptic drugs; OT = occupational therapy; PT = physical therapy</p></div></dd><dt>1. </dt><dd><div id="fars2-def.TF.6.1"><p class="no_margin">Education of parents regarding common seizure presentations is appropriate. For information on non-medical interventions and coping strategies for parents or caregivers of children diagnosed with epilepsy, see <a href="http://www.epilepsy.com/sites/core/files/atoms/files/English_Toolkit_updated%202014.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Epilepsy &#x00026; My Child Toolkit</a>.</p></div></dd></dl></div></div></div><div id="fars2-def.Developmental_Delay__Intellect"><h4>Developmental Delay / Intellectual Disability Management Issues</h4><p>The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country.</p><p><b>Ages 0-3 years.</b> Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy as well as infant mental health services, special educators and sensory impairment specialists. In the US, early intervention is a federally funded program available in all states and provides in-home services to target individual therapy needs.</p><p><b>Ages 3-5 years.</b> In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed for those who qualify based on established motor, language, social or cognitive delay. The early intervention program typically assists with this transition. Developmental preschool is center-based; however, for children too medically unstable to attend, home-based services are provided.</p><p><b>All ages.</b> Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies and to support parents in maximizing quality of life. Some issues to consider:</p><ul><li class="half_rhythm"><div>Individualized education plan (IEP) services for those who require specially designed instruction/related services</div><ul><li class="half_rhythm"><div>As required by special education law, children should be in the least restricted environment at school and included in general education as much as possible and when appropriate.</div></li><li class="half_rhythm"><div>Vision and hearing consultants should be a part of the IEP team to support access to academic material.</div></li><li class="half_rhythm"><div>PT, OT, and speech services will be provided in the IEP services to the extent that the need affects the child's access to academic material. Beyond that, private supportive therapies based on the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's needs may be considered. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.</div></li><li class="half_rhythm"><div>Services are reviewed annually to determine if any changes are needed.</div></li><li class="half_rhythm"><div>As a child enters teen years, a transition plan should be discussed and incorporated into the IEP. For those receiving IEP services, the public school district is required to provide services until age 21 years.</div></li></ul></li><li class="half_rhythm"><div>A 504 (Section 504: a federal statute that prohibits discrimination based on disability) plan can be considered for those who require accommodations or modifications such as front-of-class seating, assistive technology devices, classroom scribes, extra time between classes, modified assignments, and enlarged text.</div></li><li class="half_rhythm"><div>In the US:</div><ul><li class="half_rhythm"><div>Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.</div></li><li class="half_rhythm"><div>Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.</div></li></ul></li></ul></div><div id="fars2-def.Motor_Dysfunction"><h4>Motor Dysfunction</h4><ul><li class="half_rhythm"><div><b>Gross motor dysfunction</b></div><ul><li class="half_rhythm"><div>Physical therapy is recommended to maximize mobility and to reduce the risk for later-onset orthopedic complications (e.g., contractures, scoliosis, hip dislocation).</div></li><li class="half_rhythm"><div>Consider use of durable medical equipment and positioning devices as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, adaptive strollers).</div></li><li class="half_rhythm"><div>For muscle tone abnormalities including hypertonia or dystonia, consider involving appropriate specialists to aid in management of baclofen, tizanidine, Botox<sup>&#x000ae;</sup>, anti-parkinsonian medications, or orthopedic procedures.</div></li></ul></li><li class="half_rhythm"><div><b>Communication issues.</b> Consider evaluation for alternative means of communication (e.g., <a href="http://www.asha.org/NJC/AAC/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Augmentative and Alternative Communication</a> [AAC]) for individuals who have expressive language difficulties. An AAC evaluation can be completed by a speech-language pathologist who has expertise in the area. The evaluation will consider cognitive abilities and sensory impairments to determine the most appropriate form of communication. AAC devices can range from low-tech (e.g., picture exchange communication) to high-tech (e.g., voice-generating devices). Contrary to popular belief, AAC devices do not hinder verbal development of speech and, in many cases, can improve it.</div></li><li class="half_rhythm"><div><b>Oral-motor dysfunction</b> should be reassessed at each visit, and clinical feeding evaluations and/or radiographic swallowing studies should be obtained for choking/gagging during feeds, poor weight gain, frequent respiratory illnesses, or feeding refusal that is not otherwise explained. Feeding therapy can be helpful to improve coordination or sensory-related feeding issues. Feeds can be thickened or chilled to provide more safety, but when severe feeding dysfunction is present, an NG-tube or a G-tube may be necessary.</div></li></ul></div><div id="fars2-def.SocialBehavioral_Concerns"><h4>Social/Behavioral Concerns</h4><p>Children may qualify for and benefit from interventions used in treatment of autism spectrum disorder, including applied behavior analysis (ABA). ABA therapy is targeted to the individual child's behavioral, social, and adaptive strengths and weaknesses and is typically performed one on one with a board-certified behavior analyst.</p><p>Consultation with a developmental pediatrician may be helpful in guiding parents through appropriate behavior management strategies or providing prescription medications, such as medication used to treat attention-deficit/hyperactivity disorder, when necessary.</p><p>Concerns about serious aggressive or destructive behavior can be addressed by a pediatric psychiatrist.</p></div></div><div id="fars2-def.Surveillance"><h3>Surveillance</h3><p>Individuals with FARS2 deficiency should be evaluated periodically by an interdisciplinary team that includes a neurologist, clinical geneticist, physiatrist, and developmental specialist to assess disease progression (<a class="figpopup" href="/books/NBK538658/table/fars2-def.T.recommended_surveillance_for/?report=objectonly" target="object" rid-figpopup="figfars2defTrecommendedsurveillancefor" rid-ob="figobfars2defTrecommendedsurveillancefor">Table 7</a> and <a class="figpopup" href="/books/NBK538658/table/fars2-def.T.recommended_surveillance_for_1/?report=objectonly" target="object" rid-figpopup="figfars2defTrecommendedsurveillancefor1" rid-ob="figobfars2defTrecommendedsurveillancefor1">Table 8</a>), to maximize ambulation and communication skills, and to reduce other manifestations (<a class="figpopup" href="/books/NBK538658/table/fars2-def.T.recommended_surveillance_for_1/?report=objectonly" target="object" rid-figpopup="figfars2defTrecommendedsurveillancefor1" rid-ob="figobfars2defTrecommendedsurveillancefor1">Table 8</a>).</p><div id="fars2-def.T.recommended_surveillance_for" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with FARS2 Deficiency: Infantile-Onset Epileptic Encephalopathy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK538658/table/fars2-def.T.recommended_surveillance_for/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fars2-def.T.recommended_surveillance_for_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Feeding</b></td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess nutritional status &#x00026; feeding w/attention to poor weight gain, choking/gagging during feeds, feeding refusal not otherwise explained.</td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Respiratory</b></td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor for evidence of aspiration, respiratory insufficiency.</td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor those w/seizures as clinically indicated.</td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Development</b></td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor developmental progress &#x00026; educational needs.</td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>PT/OT evaluation for contractures, scoliosis, &#x00026; foot deformities</div></li><li class="half_rhythm"><div>Consider need for positioning devices.</div></li></ul>
</td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Miscellaneous/</b><br /><b>Other</b></td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources) &#x00026; care coordination.</td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">OT = occupational therapy; PT = physical therapy</p></div></dd></dl></div></div></div><div id="fars2-def.T.recommended_surveillance_for_1" class="table"><h3><span class="label">Table 8. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with FARS2 Deficiency: Later-Onset Spastic Paraplegia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK538658/table/fars2-def.T.recommended_surveillance_for_1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fars2-def.T.recommended_surveillance_for_1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PT/OT evaluation; assessment for contractures, scoliosis, &#x00026; foot deformities; consider need for positioning &#x00026;/or mobility devices</td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor those w/seizures as clinically indicated.</td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">If concerns for new seizure activity or progression of seizures; seizures are usually brief &#x00026; resolve over time</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Assess for new manifestations such as myoclonus, tremor, bradykinesia, dystonia, dysarthria.</td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Each visit</td></tr><tr><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Development</b></td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor developmental progress &#x00026; educational needs.</td><td headers="hd_h_fars2-def.T.recommended_surveillance_for_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">If there is concern for developmental delay / learning difficulties</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">OT = occupational therapy; PT = physical therapy</p></div></dd></dl></div></div></div></div><div id="fars2-def.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Valproic acid can induce liver failure in persons with mitochondrial diseases [<a class="bk_pop" href="#fars2-def.REF.kr_henb_hl.2000.346">Kr&#x000e4;henb&#x000fc;hl et al 2000</a>]. Some individuals with FARS2 deficiency received valproic acid and showed no evidence of liver dysfunction or worsening of existing liver disease [<a class="bk_pop" href="#fars2-def.REF.elo.2012.4521">Elo et al 2012</a>, <a class="bk_pop" href="#fars2-def.REF.walker.2016.1127">Walker et al 2016</a>, <a class="bk_pop" href="#fars2-def.REF.cho.2017.118">Cho et al 2017</a>]. Given the limited number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals reported to date, no general recommendation can be made.</p></div><div id="fars2-def.Evaluation_of_Relatives_at_Ris"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk sibs of an individual with the later-onset spastic paraplegia <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in order to identify as early as possible those who would benefit from prompt initiation of intervention for developmental and/or neurologic problems (e.g., spasticity).</p><p>See <a href="#fars2-def.Related_Genetic_Counseling_Iss">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="fars2-def.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="fars2-def.Genetic_Counseling"><h2 id="_fars2-def_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="fars2-def.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>FARS2 deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes (i.e., carriers of one <i>FARS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Unless an individual with <i>FARS2</i>-related later-onset spastic paraplegia has children with an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual or a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, his/her offspring will be obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>FARS2.</i></div></li><li class="half_rhythm"><div>To date, individuals with <i>FARS2</i>-related infantile-onset epileptic mitochondrial encephalopathy are not known to reproduce.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>FARS2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="fars2-def.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>FARS2</i> pathogenic variants in the family.</p></div><div id="fars2-def.Related_Genetic_Counseling_Iss"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#fars2-def.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="fars2-def.Prenatal_Testing_and_Preimplan"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>FARS2</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="fars2-def.Resources"><h2 id="_fars2-def_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><p>No specific resources for FARS2 Deficiency have been identified by <i>GeneReviews</i> staff.</p></div><div id="fars2-def.Molecular_Genetics"><h2 id="_fars2-def_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="fars2-def.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>FARS2 Deficiency: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK538658/table/fars2-def.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fars2-def.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_fars2-def.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_fars2-def.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_fars2-def.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_fars2-def.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_fars2-def.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_fars2-def.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/10667" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FARS2</i></a></td><td headers="hd_b_fars2-def.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=10667" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">6p25<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_fars2-def.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O95363" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Phenylalanine--tRNA ligase, mitochondrial</a></td><td headers="hd_b_fars2-def.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FARS2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FARS2</a></td><td headers="hd_b_fars2-def.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FARS2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FARS2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="fars2-def.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="fars2-def.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for FARS2 Deficiency (<a href="/omim/611592,614946,617046" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK538658/table/fars2-def.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fars2-def.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/611592" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">611592</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PHENYLALANYL-tRNA SYNTHETASE 2, MITOCHONDRIAL; FARS2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/614946" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">614946</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 14; COXPD14</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/617046" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">617046</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SPASTIC PARAPLEGIA 77, AUTOSOMAL RECESSIVE; SPG77</td></tr></tbody></table></div></div><div id="fars2-def.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><i>FARS2</i> encodes mitochondrial phenylalanine-tRNA ligase (phenylalanyl-tRNA synthetase [mtPheRS]), which transfers phenylalanine (Phe) to its cognate tRNA in mitochondria [<a class="bk_pop" href="#fars2-def.REF.bullard.1999.567">Bullard et al 1999</a>]. Human mtPheRS includes four domains: the N-terminal region (residues 37-83), the catalytic (aminoacylation) <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (residues 84-325), the linker region (residues 326-358), and the anticodon binding domain (residues 359&#x02013;451) [<a class="bk_pop" href="#fars2-def.REF.klipcan.2008.1095">Klipcan et al 2008</a>]. MtPheRS has two functional conformations. In its open "active" form, it binds tRNA and catalyzes the attachment of Phe to its cognate tRNA in the aminoacylation domain. In the closed "inactive" form, the anticodon binding domain rotates back close to the aminoacylation domain, thereby failing to exhibit an electrostatic complementarity to cognate tRNA [<a class="bk_pop" href="#fars2-def.REF.klipcan.2008.1095">Klipcan et al 2008</a>].</p><p><b>Mechanism of disease causation.</b> Different types of <i>FARS2</i> pathogenic variants result in structural and kinetic changes in MtPheRS that in turn affect one or more steps in the process of transferring Phe to its cognate tRNA in the mitochondria &#x02013; thus affecting mitochondrial protein synthesis [<a class="bk_pop" href="#fars2-def.REF.kartvelishvili.2017.1505">Kartvelishvili et al 2017</a>]. All large deletions, <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants, and <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants are <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/trans/"><i>trans</i></a> with a <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant. This suggests that complete loss of function may be incompatible with life.</p><div id="fars2-def.T.notable_fars2_pathogenic_var" class="table"><h3><span class="label">Table 9. </span></h3><div class="caption"><p>Notable <i>FARS2</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK538658/table/fars2-def.T.notable_fars2_pathogenic_var/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fars2-def.T.notable_fars2_pathogenic_var_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fars2-def.T.notable_fars2_pathogenic_var_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th><th id="hd_h_fars2-def.T.notable_fars2_pathogenic_var_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_fars2-def.T.notable_fars2_pathogenic_var_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_fars2-def.T.notable_fars2_pathogenic_var_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment [Reference]</th></tr></thead><tbody><tr><td headers="hd_h_fars2-def.T.notable_fars2_pathogenic_var_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_006567.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_006567<wbr style="display:inline-block"></wbr>​.4</a></td><td headers="hd_h_fars2-def.T.notable_fars2_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.431A&#x0003e;G</td><td headers="hd_h_fars2-def.T.notable_fars2_pathogenic_var_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr144Cys</td><td headers="hd_h_fars2-def.T.notable_fars2_pathogenic_var_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Arab <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> [<a class="bk_pop" href="#fars2-def.REF.shamseldin.2012.234">Shamseldin et al 2012</a>, <a class="bk_pop" href="#fars2-def.REF.almannai.2018.281">Almannai et al 2018</a>]</td></tr><tr><td headers="hd_h_fars2-def.T.notable_fars2_pathogenic_var_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.424G&#x0003e;T</td><td headers="hd_h_fars2-def.T.notable_fars2_pathogenic_var_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp142Tyr</td><td headers="hd_h_fars2-def.T.notable_fars2_pathogenic_var_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reported in <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state in later-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#fars2-def.REF.yang.2016.165">Yang et al 2016</a>]</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div></div></div><div id="fars2-def.References"><h2 id="_fars2-def_References_">References</h2><div id="fars2-def.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.almalki.2014.56">Almalki A, Alston CL, Parker A, Simonic I, Mehta SG, He L, Reza M, Oliveira JMA, Lightowlers RN, McFarland R, Taylor RW, Chrzanowska-Lightowlers ZMA. Mutation of the human mitochondrial phenylalanine-tRNA synthetase causes infantile-onset epilepsy and cytochrome c oxidase deficiency. <span><span class="ref-journal">Biochim Biophys Acta. </span>2014;<span class="ref-vol">1842</span>:56–64.</span> [<a href="/pmc/articles/PMC3898479/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3898479</span></a>] [<a href="/pubmed/24161539" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24161539</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.almannai.2018.281">Almannai M, Wang J, Dai H, El-Hattab AW, Faqeih EA, Saleh MA, Al Asmari A, Alwadei AH, Aljadhai YI, AlHashem A, Tabarki B, Lines MA, Grange DK, Benini R, Alsaman AS, Mahmoud A, Katsonis P, Lichtarge O, Wong L-JC. FARS2 deficiency; new cases, review of clinical, biochemical, and molecular spectra, and variants interpretation based on structural, functional, and evolutionary significance. <span><span class="ref-journal">Mol Genet Metab. </span>2018;<span class="ref-vol">125</span>:281–91.</span> [<a href="/pubmed/30177229" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30177229</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.bullard.1999.567">Bullard JM, Cai Y-C, Demeler B, Spremulli LL. Expression and characterization of a human mitochondrial phenylalanyl-tRNA synthetase. <span><span class="ref-journal">J Mol Biol. </span>1999;<span class="ref-vol">288</span>:567–77.</span> [<a href="/pubmed/10329163" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10329163</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.cho.2017.118">Cho JS, Kim SH, Kim HY, Chung T, Kim D, Jang S, Lee SB, Yoo SK, Shin J, Kim J-I, Kim H, Hwang H, Chae J-H, Choi J, Kim KJ, Lim BC. FARS2 mutation and epilepsy: possible link with early-onset epileptic encephalopathy. <span><span class="ref-journal">Epilepsy Res. </span>2017;<span class="ref-vol">129</span>:118–24.</span> [<a href="/pubmed/28043061" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28043061</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.de_kovel.2016.568">de Kovel CGF, Brilstra EH, van Kempen MJA, Van't Slot R, Nijman IJ, Afawi Z, De Jonghe P, Dj&#x000e9;mi&#x000e9; T, Guerrini R, Hardies K, Helbig I, Hendrickx R, Kanaan M, Kramer U, Lehesjoki A-EE, Lemke JR, Marini C, Mei D, M&#x000f8;ller RS, Pendziwiat M, Stamberger H, Suls A, Weckhuysen S, Koeleman BPC, et al.  Targeted sequencing of 351 candidate genes for epileptic encephalopathy in a large cohort of patients. <span><span class="ref-journal">Mol Genet Genomic Med. </span>2016;<span class="ref-vol">4</span>:568–80.</span> [<a href="/pmc/articles/PMC5023942/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5023942</span></a>] [<a href="/pubmed/27652284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27652284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.elo.2012.4521">Elo JM, Yadavalli SS, Euro L, Isohanni P, G&#x000f6;tz A, Carroll CJ, Valanne L, Alkuraya FS, Uusimaa J, Paetau A, Caruso EM, Pihko H, Ibba M, Tyynismaa H, Suomalainen A. Mitochondrial phenylalanyl-tRNA synthetase mutations underlie fatal infantile Alpers encephalopathy. <span><span class="ref-journal">Hum Mol Genet. </span>2012;<span class="ref-vol">21</span>:4521–9.</span> [<a href="/pubmed/22833457" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22833457</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.kartvelishvili.2017.1505">Kartvelishvili E, Tworowski D, Vernon H, Moor N, Wang J, Wong L, Chrzanowska-Lightowlers Z, Safro M. Kinetic and structural changes in H smt PheRS, induced by pathogenic mutations in human FARS 2. <span><span class="ref-journal">Protein Sci. </span>2017;<span class="ref-vol">26</span>:1505–16.</span> [<a href="/pmc/articles/PMC5521548/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5521548</span></a>] [<a href="/pubmed/28419689" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28419689</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.klipcan.2008.1095">Klipcan L, Levin I, Kessler N, Moor N, Finarov I, Safro M. The tRNA-induced conformational activation of human mitochondrial phenylalanyl-tRNA synthetase. <span><span class="ref-journal">Structure. </span>2008;<span class="ref-vol">16</span>:1095–1104.</span> [<a href="/pubmed/18611382" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18611382</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.kr_henb_hl.2000.346">Kr&#x000e4;henb&#x000fc;hl S, Brandner S, Kleinle S, Liechti S, Straumann D. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. <span><span class="ref-journal">Liver. </span>2000;<span class="ref-vol">20</span>:346–8.</span> [<a href="/pubmed/10959815" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10959815</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.raviglione.2016.3004">Raviglione F, Conte G, Ghezzi D, Parazzini C, Righini A, Vergaro R, Legati A, Spaccini L, Gasperini S, Garavaglia B, Mastrangelo M. Clinical findings in a patient with FARS2 mutations and early-infantile-encephalopathy with epilepsy. <span><span class="ref-journal">Am J Med Genet A. </span>2016;<span class="ref-vol">170</span>:3004–7.</span> [<a href="/pubmed/27549011" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27549011</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.sahai.2018.1128">Sahai SK, Steiner RE, Au MG, Graham JM, Salamon N, Ibba M, Pierson TM. FARS2 mutations presenting with pure spastic paraplegia and lesions of the dentate nuclei. <span><span class="ref-journal">Ann Clin Transl Neurol. </span>2018;<span class="ref-vol">5</span>:1128–33.</span> [<a href="/pmc/articles/PMC6144452/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6144452</span></a>] [<a href="/pubmed/30250868" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30250868</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.shamseldin.2012.234">Shamseldin HE, Alshammari M, Al-Sheddi T, Salih MA, Alkhalidi H, Kentab A, Repetto GM, Hashem M, Alkuraya FS. Genomic analysis of mitochondrial diseases in a consanguineous population reveals novel candidate disease genes. <span><span class="ref-journal">J Med Genet. </span>2012;<span class="ref-vol">49</span>:234–41.</span> [<a href="/pubmed/22499341" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22499341</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.vantroys.2017.172">Vantroys E, Larson A, Friederich M, Knight K, Swanson MA, Powell CA, Smet J, Vergult S, De Paepe B, Seneca S, Roeyers H, Menten B, Minczuk M, Vanlander A, Van Hove J, Van Coster R. New insights into the phenotype of FARS2 deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2017;<span class="ref-vol">122</span>:172–81.</span> [<a href="/pmc/articles/PMC5734183/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5734183</span></a>] [<a href="/pubmed/29126765" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29126765</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.vernon.2015.1147">Vernon HJ, McClellan R, Batista DAS, Naidu S. Mutations in FARS2 and non-fatal mitochondrial dysfunction in two siblings. <span><span class="ref-journal">Am J Med Genet A. </span>2015;<span class="ref-vol">167A</span>:1147–51.</span> [<a href="/pubmed/25851414" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25851414</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.walker.2016.1127">Walker MA, Mohler KP, Hopkins KW, Oakley DH, Sweetser DA, Ibba M, Frosch MP, Thibert RL. Novel compound heterozygous mutations expand the recognized phenotypes of FARS2-linked disease. <span><span class="ref-journal">J Child Neurol. </span>2016;<span class="ref-vol">31</span>:1127–37.</span> [<a href="/pmc/articles/PMC4981184/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4981184</span></a>] [<a href="/pubmed/27095821" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27095821</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="fars2-def.REF.yang.2016.165">Yang Y, Liu W, Fang Z, Shi J, Che F, He C, Yao L, Wang E, Wu Y. A newly identified missense mutation in FARS2 causes autosomal-recessive spastic paraplegia. <span><span class="ref-journal">Hum Mutat. </span>2016;<span class="ref-vol">37</span>:165–9.</span> [<a href="/pubmed/26553276" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26553276</span></a>]</div></li></ul></div></div><div id="fars2-def.Chapter_Notes"><h2 id="_fars2-def_Chapter_Notes_">Chapter Notes</h2><div id="fars2-def.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>14 March 2019 (bp) Review posted live</div></li><li class="half_rhythm"><div>9 November 2018 (ljw) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK538658</span><span class="label">PMID: <a href="/pubmed/30869852" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">30869852</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ee/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/fbln5-cutis-laxa/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK538658&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK538658/?report=reader">PubReader</a></li><li><a href="/books/NBK538658/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK538658" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK538658" style="display:none" title="Cite this Page"><div class="bk_tt">Almannai M, Faqeih E, El-Hattab AW, et al. FARS2 Deficiency. 2019 Mar 14. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK538658/pdf/Bookshelf_NBK538658.pdf">PDF version of this page</a> (470K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#fars2-def.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#fars2-def.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#fars2-def.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#fars2-def.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#fars2-def.Genetically_Related_Allelic_Di" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#fars2-def.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#fars2-def.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#fars2-def.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#fars2-def.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#fars2-def.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#fars2-def.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#fars2-def.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=10667[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FARS2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4740820" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4740820" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4740820" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4740820" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30543385" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> AP-4-Associated Hereditary Spastic Paraplegia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> AP-4-Associated Hereditary Spastic Paraplegia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ebrahimi-Fakhari D, Behne R, Davies AK, Hirst J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24741716" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">RRM2B</i>-Related Mitochondrial Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">RRM2B</i>-Related Mitochondrial Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gorman GS, Taylor RW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301416" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Krabbe Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Krabbe Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Orsini JJ, Escolar ML, Wasserstein MP, Caggana M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29300443" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> RAB18 Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> RAB18 Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Handley M, Sheridan E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301309" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Arylsulfatase A Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Arylsulfatase A Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gomez-Ospina N. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=30869852" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=30869852" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc929575f66d18aac5878b">FARS2 Deficiency - GeneReviews®</a><div class="ralinkpop offscreen_noflow">FARS2 Deficiency - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T04:21:25-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE888116DFC890010000000004A3023E&amp;ncbi_session=CE888116DFC92951_1187SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK538658%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK538658&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK538658/&amp;ncbi_pagename=FARS2 Deficiency - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE888116DFC92951_1187SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>